Sanofi Turns The Screws On Genzyme
Sanofi-Aventis goes public with a $69-per-share offer for Genzyme, while the biotech rebuffs the offer as "opportunistic."
Sanofi-Aventis goes public with a $69-per-share offer for Genzyme, while the biotech rebuffs the offer as "opportunistic."